(Q58614457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

title

Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Olusola Olafuyi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

language of work or name

English

0 references

publication date

3 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmaceutical Sciences

2 May 2020

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

661-673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

on focus list of Wikimedia project

2 May 2020

WikiProject Zika Corpus

0 references

cites work

Advances in research on Zika virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Zika virus, a cause of fever in Central Java, Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Concurrent outbreaks of dengue, chikungunya and Zika virus infections – an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Zika Virus Outbreak on Yap Island, Federated States of Micronesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Current Zika virus epidemiology and recent epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Congenital Zika Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Zika Virus Associated with Microcephaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Notes from the Field : Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses — Brazil, 2015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Zika Virus Infection in Pregnant Women in Rio de Janeiro — Preliminary Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pregnancy outcome following first trimester exposure to chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

STUDIES ON THE PHARMACOLOGY OF CHLOROQUINE. RECOMMENDATIONS FOR THE TREATMENT OF CHLOROQUINE RETINOPATHY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Inhibition of Human Immunodeficiency Virus Infectivity by Chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

In vitro inhibition of human influenza A virus replication by chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Placental and milk transfer of chloroquine in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Should chloroquine be laid to rest?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Chloroquine-resistant malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetics of drugs in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetic studies in pregnant women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Serum protein binding of drugs during and after pregnancy in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Increase in plasma volume during normal pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetic changes during pregnancy and their clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Plasma volume in normal first pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Developing regional weight-for-age growth references for malaria-endemic countries to optimize age-based dosing of antimalarials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Tissue and blood concentrations of chloroquine following chronic administration in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Development and evaluation of a generic physiologically based pharmacokinetic model for children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

PBPK modeling and simulation in drug research and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Effect of food on bioavailability of chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Disposition of chloroquine in man after single intravenous and oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The application of physiologically-based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Physiologic and pharmacokinetic changes in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Enhanced urinary albumin excretion after 35 weeks of gestation and during labour in normal pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Immunogold cytochemistry of the blood-brain barrier glucose transporter GLUT1 and endogenous albumin in the developing human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Resistance to chloroquine therapy in pregnant women with malaria parasitemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Antimalarial drugs in pregnancy: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2018.10.056

10.1016/J.XPHS.2018.10.056

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30399360%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference